Cancer Vanguard Biosimilars Project – Web link now live

We can now confirm that the Cancer Vanguard Biosimilars Project learning materials and resources are available on the Cancer Vanguard website – link below:
 
http://cancervanguard.nhs.uk/biosimilars-getting-it-right-first-time
 
The site currently has materials available including:

  • Biosimilars adoption process timeline
  • Biosimilars principles – education presentation
  • Service impact study
  • Education impact assessment
  • Biosimilar policy

A PIL and Q&A document are currently in development and will be uploaded to the site in the near future. A further communication will be sent out when available.
 
Please circulate this to relevant NHS stakeholders that you feel will benefit from the information.
 

Latest News

By BOPA Research Committee on 25th April 2024

Survey: Pharmacogenomic Panel Testing in Cancer: UK Oncology Professionals

Please consider completing our BOPA member survey on the use of pharmacogenomic panel testing in people with solid tumours. Survey information I’m a pharmacist and pre-doctoral research fellow researching the…

Read article
By BOPA Research committee on 25th April 2024

NIHR Associate Principal Investigator (PI) Scheme is continuing to host Research Learning Lectures

The NIHR Associate Principal Investigator (PI) Scheme is continuing to host the Research Learning Lectures; a series of lectures for anyone in Health and Social Care interested in learning more about research.…

Read article
By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article